Ibio: "I've got to do a little more work on that $560 million bad boy, and we will come back. Interesting chart."
Vaxart: "Did you read the article about the insider selling? To me it was a — I didn't like the tone of it, let's put it that way. I didn't like the tone of Vaxart."
Dynatrace: "We like Dynatrace. Look, it's been a real winner. I don't know. It's a very expensive stock in terms of price-to-earnings ratio, so I don't think anyone would buy it. I think you should stick with it."
Rosetta Stone: "This is an interesting, good household brand stock."